MX2018010367A - Titulacion de cebranopadol. - Google Patents

Titulacion de cebranopadol.

Info

Publication number
MX2018010367A
MX2018010367A MX2018010367A MX2018010367A MX2018010367A MX 2018010367 A MX2018010367 A MX 2018010367A MX 2018010367 A MX2018010367 A MX 2018010367A MX 2018010367 A MX2018010367 A MX 2018010367A MX 2018010367 A MX2018010367 A MX 2018010367A
Authority
MX
Mexico
Prior art keywords
cebranopadol
daily dose
administration interval
administered
administration
Prior art date
Application number
MX2018010367A
Other languages
English (en)
Inventor
Wang Shaonan
Piana Chiara
Bursi Roberta
Original Assignee
Guenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guenenthal Gmbh filed Critical Guenenthal Gmbh
Publication of MX2018010367A publication Critical patent/MX2018010367A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a Cebranopadol para su uso en el tratamiento de dolor, donde Cebranopadol se administra de acuerdo con un régimen de administración que comprende (i) un primer intervalo de administración, que dura al menos 2 días consecutivos, donde una primera dosis diaria de Cebranopadol se administra todos los días del primer intervalo de administración; y (ii) un segundo intervalo de administración, que dura al menos 2 días consecutivos y que le sigue directamente al primer intervalo de administración sin interrupción, donde una segunda dosis diaria de Cebranopadol se administra todos los días del segundo intervalo de administración; donde la primera dosis diaria de Cebranopadol es menor que la segunda dosis diaria de Cebranopadol.
MX2018010367A 2016-02-29 2017-02-28 Titulacion de cebranopadol. MX2018010367A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16157868 2016-02-29
EP16020302 2016-08-11
PCT/EP2017/025034 WO2017148595A1 (en) 2016-02-29 2017-02-28 Titration of cebranopadol

Publications (1)

Publication Number Publication Date
MX2018010367A true MX2018010367A (es) 2018-12-10

Family

ID=58185482

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010367A MX2018010367A (es) 2016-02-29 2017-02-28 Titulacion de cebranopadol.

Country Status (10)

Country Link
US (2) US11229625B2 (es)
EP (1) EP3423054A1 (es)
JP (2) JP7373904B2 (es)
CN (2) CN109069483A (es)
AU (1) AU2017226830B2 (es)
BR (1) BR112018017167A2 (es)
CA (1) CA3015420C (es)
IL (1) IL261133A (es)
MX (1) MX2018010367A (es)
WO (1) WO2017148595A1 (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1126834A1 (en) * 1998-11-02 2001-08-29 Ortho-McNeil Pharmaceutical, Inc. Analgesic regimen
US6339105B1 (en) * 1999-10-12 2002-01-15 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
WO2004054553A1 (en) * 2002-12-13 2004-07-01 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
US7413749B2 (en) * 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
HUE028436T2 (hu) 2010-08-04 2016-12-28 Gruenenthal Gmbh Gyógyszerészeti adagolási forma, amely tartalmaz-6'-fluor-(N-metil- vagy N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-spiro[ciklohexán-1,1'-pirano[3,4B]indol]-4-amint
PL2600838T3 (pl) 2010-08-04 2016-02-29 Gruenenthal Gmbh Farmaceutyczna postać dawkowania zawierająca 6'-fluoro-(N-metylo- lub N,N-dimetylo)-4-fenylo-4'9'-dihydro-3'H-spiro[cykloheksano-1,1'-pirano[3,4b]indolo]-4-aminę
TR201808244T4 (tr) * 2010-08-04 2018-07-23 Gruenenthal Gmbh Nöropatik ağrının tedavisi için 6'-floro-(n-metil- veya n,n-dimetil-)-4-fenil-4',9'-dihidro-3'h-spiro[siklohekzan-1,1'-pirano[3,4,b]indol]-4-amin içeren farmasötik dozaj formu.
AU2011287956B2 (en) 2010-08-04 2015-01-22 Grunenthal Gmbh Pharmaceutical dosage form comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4,9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
LT2729470T (lt) 2011-07-08 2017-08-25 Grünenthal GmbH Kristalinis (1r,4r)-6`-fluor-n,n-dimetil-4-fenil-4`,9`-dihidro-3`h-spiro[cikloheksan-1,1`-pirano[3,4,b]indol]-4-aminas

Also Published As

Publication number Publication date
AU2017226830B2 (en) 2021-06-24
CA3015420A1 (en) 2017-09-08
CA3015420C (en) 2023-09-26
US11229625B2 (en) 2022-01-25
JP7373904B2 (ja) 2023-11-06
US20180369199A1 (en) 2018-12-27
IL261133A (en) 2018-10-31
AU2017226830A1 (en) 2018-08-16
CN118286209A (zh) 2024-07-05
JP2021169472A (ja) 2021-10-28
BR112018017167A2 (pt) 2019-01-02
US20220110914A1 (en) 2022-04-14
JP2019507148A (ja) 2019-03-14
WO2017148595A1 (en) 2017-09-08
EP3423054A1 (en) 2019-01-09
CN109069483A (zh) 2018-12-21

Similar Documents

Publication Publication Date Title
WO2018234568A3 (en) HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
NZ751137A (en) System, device and methods of seed treatment
EA201890507A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2020011817A (es) Metodos para tratar el linfoma.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
JOP20220092A1 (ar) جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر
MX2022000143A (es) Metodos novedosos.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2021014523A (es) Metodos para tratar colangiocarcinoma.
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2018010367A (es) Titulacion de cebranopadol.
MX2020013385A (es) Metodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropion.
MX2020010938A (es) Medicamento para prevenir y/o tratar el dolor y/o la fiebre, producto compuesto y uso del mismo.
PH12017501918A1 (en) Multi-peptide composition
MX2021004511A (es) Medicamento para el tratamiento y/o mejora de la septicemia asociada con la anomalia de la coagulacion.
MX2023005681A (es) Composicion farmaceutica para el tratamiento contra el dolor agudo y cronico, que contiene polmacoxib y tramadol.
UA117853U (uk) Спосіб лікування гострої респіраторної вірусної інфекції у дітей
EA202190033A1 (ru) Соединения пиразола и имидазола для ингибирования il-17 и ror-гамма